10-Q: Century Therapeutics Q1 2026 Financials: Revenue Drop, Cash Burn Continues

Century Therapeutics reports a significant drop in collaboration revenue and continued operating losses in its Q1 2026 filing, while highlighting progress in its iPSC cell therapy pipeline.

Summary

• Century Therapeutics, Inc. filed its quarterly report for the period ended March 31, 2026.
• The company reported zero collaboration revenue for the quarter, a stark contrast to the $109.2 million recognized in the same period of 2025, due to the termination of the Bristol-Myers Squibb collaboration agreement.
• Operating expenses decreased to $23.7 million from $35.0 million in the prior year's quarter, primarily driven by reduced research and development spending.
• The company incurred a net loss of $21.6 million for the quarter, compared to a net income of $76.6 million in Q1 2025.
• Cash and cash equivalents, along with short-term investments, totaled $134.8 million as of March 31, 2026.
• The company believes its current cash and investments are sufficient to fund operations into the first quarter of 2029.
• Significant progress is noted in advancing its iPSC-derived cell therapy pipeline, with IND-enabling studies underway for CNTY-813 and CNTY-308.
• A private placement in January 2026 raised approximately $126.4 million in net proceeds.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the complete loss of collaboration revenue and the resulting net loss, despite positive developments in the pipeline and a recent capital raise.

Positives

• Successful completion of a $126.4 million private placement in January 2026, bolstering the company's cash position.
• Projected cash runway extending into the first quarter of 2029, providing a significant buffer for ongoing operations and development.
• Advancement of key pipeline candidates, CNTY-813 (for Type 1 Diabetes) and CNTY-308 (for B-cell-mediated diseases), into IND-enabling studies.
• Continued progress in developing its allogeneic cell therapy platform utilizing iPSCs, including proprietary Allo-Evasion technology.
• Reduction in operating expenses, particularly in research and development, indicating a focus on efficiency.

Negatives

• Complete cessation of collaboration revenue, dropping from $109.2 million in Q1 2025 to $0 in Q1 2026, due to the termination of the Bristol-Myers Squibb agreement.
• Net loss of $21.6 million for the quarter, highlighting the ongoing cash burn characteristic of early-stage biotechnology companies.
• Significant decrease in cash from operating activities, with $25.3 million used in Q1 2026 compared to $34.6 million in Q1 2025.
• The company anticipates substantial increases in expenses and operating losses in the future.

Risks

• The company has a limited operating history and its prospects are subject to risks and uncertainties common in the biotechnology and pharmaceutical industries, including the uncertainty of obtaining additional financing and achieving future profitability.
• The early preclinical and clinical nature of its business means there is no guarantee of successfully advancing product candidates through development, preclinical studies, and clinical trials.
• The novelty of its iPSC-derived cell therapy approach presents challenges and the success of competing therapies could impact its prospects.
• Regulatory clearance from agencies like the FDA is required for commercial sales, and denial or delay could have a material adverse impact.
• The company's ability to raise additional capital on acceptable terms is crucial for its continued operations and future development.
• The volatility of capital markets and macroeconomic factors such as inflation, banking instability, and geopolitical tensions could impact the company's financial condition.
• The company's ability to attract and retain key management and scientific personnel is critical.

Future Outlook

The company anticipates substantial increases in expenses and operating losses in the foreseeable future due to ongoing research and development activities, progression of product candidates, expansion of manufacturing capabilities, and costs associated with operating as a public company. Future financing will likely be required to fund operations, including preclinical studies, clinical trials, and potential commercialization of approved product candidates. Management believes current cash and investments are sufficient to fund operations into the first quarter of 2029.

Management Comments

• We believe such 'off-the-shelf' therapies have the potential to overcome the limitations of first-generation cell therapies by providing readily available treatments more quickly, reliably, at greater scale, and to a broader patient population.
• We are unique in the breadth of cell types we can generate from iPSCs, including iPSC-derived islet cells, iPSC-derived CD4+ and CD8+ab T cells, or ab iT cells, and iPSC- natural killer cells, or iNK cells.
• Based on our current business plans, we believe our cash, cash equivalents and investments as of March 31, 2026 of $217.0 million will be sufficient for us to fund our operating expenses and capital expenditures requirements into the first quarter of 2029.
• We anticipate that our expenses and operating losses will increase substantially over the foreseeable future.

Industry Context

StockSavvy.ai notes that Century Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on advanced cell therapies. The significant drop in collaboration revenue highlights the inherent risks in such partnerships, while the continued investment in R&D and pipeline advancement reflects the industry's long development cycles and the need for substantial funding.

Comparison to Industry Standards

• The net loss of $21.6 million for the quarter is consistent with many early-stage biotechnology companies that are heavily investing in research and development without significant product revenue.
• The cash burn rate of approximately $25.3 million for the quarter is within the typical range for companies at this stage of development, especially those with multiple pipeline candidates.
• The successful completion of a private placement raising over $126 million is a positive indicator in a challenging market, demonstrating investor confidence in the company's technology and pipeline, though the per-share price reflects current market valuations for pre-revenue biotech firms.
• The projected cash runway into Q1 2029 is a strong positive, exceeding the typical 18-24 month runway often considered a minimum for such companies, providing a more stable outlook for continued development.

Legal Proceedings

• Management believes there are currently no claims or actions pending against the company that would have a material adverse effect on its results of operations, financial condition, or cash flows.

Stakeholder Impact

• Shareholders: Dilution risk from potential future equity offerings, but also potential upside from pipeline advancements. The recent capital raise at a lower price point may have impacted existing shareholders.
• Employees: Continued employment and stock-based compensation are contingent on the company's ability to secure future funding and achieve milestones. Reductions in R&D staff were noted.
• Suppliers/Partners: Continued business relationships are dependent on the company's financial stability and ongoing projects. The termination of the BMS collaboration impacts FCDI and Catalent's potential future revenue streams from Century.
• Creditors: The company's significant accumulated deficit and reliance on future financing suggest a higher risk profile for creditors, though current liquidity appears sufficient for the near to medium term.

Next Steps

• Submit an IND for CNTY-813 in the fourth quarter of 2026.
• Initiate clinical studies for CNTY-308 in 2026, following successful completion of IND-enabling studies and regulatory approval.
• Continue to advance iPSC cell therapy platforms and progress preclinical and clinical development of product candidates.
• Expand and validate internal and external manufacturing capabilities.
• Seek regulatory approvals for product candidates that successfully complete clinical trials.
• Maintain, expand, protect, and enforce intellectual property portfolio.
• Acquire or in-license other product candidates and technologies.

Key Dates

Recommendation

The company's significant revenue drop and net loss are concerning, but the successful capital raise and progress in its advanced cell therapy pipeline provide a basis for holding. Investors should monitor future financing needs, clinical trial progress, and the ability to generate future revenue streams.

Keywords

Century Therapeutics, Form 10-Q, Biotechnology, Cell Therapy, iPSC, Allogeneic, Autoimmune Diseases, Cancer, Clinical Trials, IND-enabling studies, Financial Results, Collaboration Revenue, Net Loss, Capital Raise